Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Syngene Invests US$9.5 (INR 788 crores) to Open New Facility in India

Introduction:
Syngene with an investment of US$9.5 (INR 788 crores) plans to build new state-of-the-art research laboratories in Hyderabad, India. This will be an extension to its existing research campus.

Features:
The expansion of operations in Genome Valley, includes the new research and development facility for the development of biotech industry. 

The facility also houses a cutting-edge PROTAC laboratory dedicated to conducting advanced research on disease-causing proteins, which play a central role in illnesses like cancer. Additionally, there is a central compound management facility, serving as the central storage hub for all compounds synthesized by scientists.

The research conducted at the new facility with a primary focus on discovery chemistry and biology is pivotal for the advancement of the pharmaceutical industry. These areas are fundamental in drug discovery and development.

The facility will provide the essential infrastructure and support systems required to empower cutting-edge life science research and development (R&D) activities.

The new campus aims to generate up to 1000 science-related jobs within the next five years. 

Construction of the new facilities is scheduled to commence in 2024.

Specifications:
Name    Syngene
Type      New Construction
Budget   US$9.5 (INR 788 crores)
Year        2024

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024